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Role of procalcitonin in 
paediatric burn wound 
sepsis 
To the Editor: Wound infection is a leading 
cause of mortality and morbidity in patients 
with burns. It can cause burn wound 
conversion, spread systemically, delay 
wound healing and lead to hypertrophic 
scars, and it increases mortality by 50 - 
60% despite improvements in antimicrobial 
management. Many factors contribute to 
the high incidence of burn wound infection, 
i.e. delayed initial care, deep burns, burns 
>30% of the total body surface area, 
delayed wound closure and various host 
factors, such as malnutrition, comorbidities 
and immunosuppression. Other factors 
include the bioburden and virulence of the 
bacterial infection. The early diagnosis of 
burn sepsis is of crucial importance, as 
it reduces mortality and morbidity, and 
shortens antibiotic treatment and hospital 
stay. Furthermore, the unnecessary use of 
antibiotics has side-effects and can lead 
to antibiotic resistance, both of which are 
detrimental to the burn patient. 
Burn wound infection remains a clinical 
and laboratory diagnosis and can be difficult 
to distinguish from the hyperdynamic, 
hypermetabolic status associated with 
burn injuries and systemic inflammatory 
response syndrome (SIRS). Because of the 
inflammatory response and immunoparesis 
associated with burns, standard laboratory 
tests for sepsis are difficult to interpret.[1] 
As the clinical picture between SIRS and 
sepsis can overlap and blood culture yields 
are typically low, diagnostic predicaments 
are created that have implications for 
therapeutic choices. 
In our paediatric burns unit, we have 
introduced specific measures to reduce the 
infection rate, detect burn sepsis early and 
differentiate SIRS from sepsis. Diagnostic 
uncertainty is common in the burns patient, 
despite careful physical examination, radio -
graphs, tissue biopsies and various labora-
tory tests. 
We introduced procalcitonin testing 
to assist with this diagnostic dilemma. 
Procalcitonin is a 116 amino acid protein 
and the precursor of calcitonin. It becomes 
detectable within 2 - 4 hours after a trig-
gering inflammatory stimulus, peaking at 
12 - 24 hours and remaining elevated for 
24 hours. Procalcitonin secretion parallels 
the severity of the bacterial inflammatory 
insult, with higher levels associated with 
more severe disease and declining levels with 
resolution of illness. It does not increase in 
the case of viral or fungal burn infection.[2]
In our unit, patients are thoroughly washed 
from head to toe, including the burnt area. 
All loose skin is gently removed and hair is 
shaved where burns extend into the hairline. 
This has become an essential component of 
our initial care and should ideally be done 
within 8 hours after a burn. Furthermore, 
deep burns are excised and grafted early; 
measures are taken to promote primary 
wound healing and no prophylactic anti-
biotics are used. We distinguish SIRS 
from sepsis by using the American Burn 
Association SIRS/sepsis criteria and we also 
view procalcitonin levels as a specific marker 
of bacterial sepsis (Fig. 1 and Table 1 ).[3]
In a recent study in our unit, sepsis was 
suspected in 74 infants; only 15 (20.3%) had 
positive blood cultures. Procalcitonin levels 
in those with positive blood cultures were on 
average 39.4 ng/mL (95% confidence interval 
(CI) 0.1 - 1 303). All children survived.[4] These 
results are supported by the meta-analysis by 
Cabral et al.,[5] who found procalcitonin to 
be 46.8 ng/mL (95% CI 2.5 - 91.1) in patients 
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Day post burn: .......
TBSA of burn: .........
SCORE: /4
SIRS: ≥2 of
• Temperature >38°C or <36°C 
• Pulse (children >2 SD for age, bradycardia <10th percentile) 
• RR (children >2 SD for age) 
• WCC (children leukocyte count elevated or depressed for age) or >10% immature neutrophils
SEPSIS: at least 3 of the following
• Temperature >39°C or <36.5ºC                                               (....... °C) 
• Progressive tachycardia (children >2 SD)                            (....... /min) 
• Progressive tachypnoea >30/min (children >2 SD)         (....... /min) 
• Refractory hypotension (children <2 SD for age)             (....... /....... mmHg) 
• Leukocytosis >12 000 cells/µL or <4 000 cells/µL            (....... cells/µL) 
• Thrombocytopenia <100 000 (children <2 SD)                 (.......) 
• Hyperglycaemia >6.1 mmol/L                                                (....... mmol/L) 
• Inability to tolerate enteral feeds >24 hours 
        • Abdominal distention 
        • Residual volumes >150  mL/h children 
        • Diarrhoea >400 mL/day 
INFECTION: at least one of the following 
• Positive culture or histology ......................................................................................................
• Strong suspicion of sepsis  .........................................................................................................
• Retrospective response to antibiotics ....................................................................................
SCORE: /8
SCORE: /7 
Radiographical ndings ................................................ Skin punch biopsy .......................... 
PCT value ..................... Skin swab result ..................... Blood culture result ...................... 
Bands >10% (Yes/No) ...................................................... 
Comment: SIRS only Possibly septic Very likely septic 
Decision of antibiotic usage: Yes/No 
Choice of antibiotic ..........................................................
Patient details
Fig. 1. Paediatric burns SIRS and sepsis log. (TBSA = total body surface area; SIRS = systemic 
inflammatory response syndrome; SD = standard deviation; RR = respiratory rate/min; WCC = white 
cell count; PCT = procalcitonin.)
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with severe burn sepsis and 0.9 ng/mL (95% CI 0.1 - 1.6) in the non-
infected group. A Taiwanese study by Wu et al.[6] showed procalcito-
nin levels to be on average 47.19 ng/mL in burn patients with septic 
shock and positive blood cultures and 29.54 ng/mL in those with 
positive cultures without septic shock. In the culture-negative group, 
the average procalcitonin was 1.81 ng/mL. Staphylococcal toxic shock 
syndromes typically give procalcitonin levels in the low hundreds 
and streptococcal toxic shock syndrome can give procalcitonin levels 
≥1 000 ng/mL. Provided correct treatment is rendered, survival is 
excellent.
Our indication for testing procalcitonin would be a child who 
has confirmed SIRS and at least 3/8 points, indicating sepsis on the 
American Burn Association SIRS/sepsis chart (Fig. 1). In the first 
48 hours, children with signs of staphylococcal toxic shock syndrome 
(rash, fever, vomiting and diarrhoea) or ongoing tachycardia despite 
adequate pain control and resuscitation, would also be considered 
for testing. This is to identify toxic shock syndromes that occur in 
the first 72 hours. At a procalcitonin value of >2 ng/mL, we consider 
initiating intravenous antibiotics, although recent studies suggest 
that levels as low as 0.5 - 1.5 ng/mL may indicate sepsis.[7-9] Typically, 
blood cultures only become positive after hours or days, which delays 
appropriate goal-directed antibiotic therapy. Because of the half-life 
of procalcitonin (22 - 35 hours) and the cost of testing, re-testing 
should be performed after 48 - 72 hours, unless the clinical picture 
indicates non-responsiveness to the chosen antibiotic.[8] Antibiotic 
treatment may be discontinued with a procalcitonin value of ˂2 ng/mL 
and if the clinical picture shows improvement.
Although testing is relatively costly (ZAR388.00 per test), we 
consider it to be cost-effective when taking into account the risk of 
delayed therapy, the cost of prolonged hospital stay and antibiotic 
treatment when not indicated, including that of intravenous cannulas, 
lines and fluids required to deliver antibiotic therapy. 
In conclusion, procalcitonin testing is used in our burns unit as an 
early indicator of sepsis, toxic shock syndromes, monitoring response 
and stewardship to antimicrobial therapy. 
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Table 1. Paediatric values at 2 standard deviations of normal
Age
Tachycardia, 
bpm
Respiratory rate, 
breaths/min
Systolic blood 
pressure, mmHg
White cell count, 
× 109/L
Thrombocyte 
count, /µL
0 days - 1 week >180 >50 <65 >34 <150 000
>1 week - 1 month >180 >40 <75 >19.5  
<5
<150 000
>1 month - 1 year >180 >34 <94 >17.5 
<5
<150 000
2 - 5 years >140 >22 <100 >15.5  
<6
<150 000
6 - 12 years >130 >18 <105 >13.5  
<4.5
<150 000
13 - 17 years >110 >14 <117 >11 
<4.5
<150 000
